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I. INTRODUCTION
Recent years have witnessed a rapidly growing crisis in antimicrobial resistance, especially among 
microorganisms that cause nosocomial infections. The first antibiotic, penicillin, was discovered in 1929 
by Sir Alexander Fleming. Penicillin became generally available for the treatment of bacterial infections, 
and particularly those caused by staphylococci and streptococci, around 1946. The period of the late 1940s 
and the early 1950s saw the discovery and introduction of streptomycin, chloramphenicol and tetracycline, 
and the age of bacterial chemotherapy came into full being. These antibiotics were effective against the 
full array of bacterial pathogens, including Gram-positive and Gram-negative bacteria (e.g. Staphylococcus 
aureus, Escherichia coli and Pseudomonas aeruginosa), intracellular parasites and tuberculosis bacillus. 
However, by 1957, during a Shigella outbreak in Japan, a strain of dysentery bacillus was isolated which 
was multiple drug-resistant, exhibiting resistance to chloramphenicol, tetracycline, streptomycin and 
sulphonamide. 
Drug-resistant infectious agents are an increasingly important public health concern. Antimicrobial 
resistance is becoming a factor in virtually all hospital-acquired or nosocomial infections. Resistance to 
antimicrobial agents among bacteria and fungi is a persistent problem that complicates the management 
of critically ill patients. 
S. aureus and enterococci are the most commonly isolated bacteria that cause nosocomial infections. 
Among those giving rise to therapeutic problems are methicillin-resistant staphylococci and vancomycin-
resistant enterococci. When penicillin was introduced in 1944 over 94% of S. aureus isolates were 
susceptible; by 1950, half were resistant. By 1960, many hospitals had outbreaks of virulent multiresistant 
S. aureus. These were overcome with penicillinase-stable penicillins, but victory was brief; strains of 
methicillin-resistant S. aureus (MRSAs) were recorded even in the year of the drug’s launch. MRSAs 
owe their behaviour to an additional, penicillin-resistant peptidoglycan transpeptidase, PBP-2’, encoded 
by mecA. Their spread is clonal, with transfer of mecA being extremely rare. MRSAs accumulated and 
then declined in the 1960s and 1970s, but became re-established in the early 1980s. The wide-ranging 
application of antimicrobials in medical and veterinary practice, the usage of antibiotics in agriculture, 
and the common use of antiseptics and disinfectants result in a selection pressure. The administration 
of antibiotics directly selects variants resistant to different antibiotics or disinfectants. The same genetic 
elements (e.g. qac or smr) that confer resistance to some disinfectants are often present on the same 
plasmid conferring resistance to antibiotics.
2. AIMS OF THE STUDY
The frequency among clinical isolates of antibiotic-resistant strains, including poly- and multiresistant 
ones, continues to increase. These antibiotic-resistant bacteria often cause life-threatening infections. To 
overcome these situations, we need new antibiotics or new drug combinations with which to treat antibiotic-
resistant bacterial infections.  In this thesis, I will focus on in vitro models of combination chemotherapy 
against laboratory strains used as model and antibiotic-resistant clinical isolates. Accordingly, the following 
questions will be studied in detail:
 The activities of resistance modifiers in modifing bacterial sensitivity to given antibiotics (ampicillin,  •
chloramphenicol, erythromycin and tetracyline) will be studied by using various resistance modifiers 
(promethazine, verapamil, clomipramine). The antibacterial effects of promethazine, verapamil and 
clomipramine will be studied as standard "group representative" resistance modifiers on different 
bacterial species (E. coli, P. aeruginosa, S. aureus and S. epidermidis). 
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The antibacterial effects of various newly synthetized calcium channel blockers, nifedipine  •
(NP) analogues 3,5-diacetyl-1,4-dihydropyridines (AcDHPs)/G1-G11/ and 3,5-dibenzoyl-1,4-
dihydropyridines (BzDHPs) /GB1-GB15/, and will be studied on different resistant E. coli strains 
from clinical specimens. 
The combinations of different resistance modifiers (AcDHPs) and (B zDHPs) with various  •
antibiotics, such as ampicillin, erythromycin, tetracycline and chloramphanicol, will be studied via a 
checkerboard method on some Gram-negative strains. Oxacillin with promethazine, or verapamil or 
imipramine will be studied in combination on clinical Gram-positive strains.
The plasmid-curing effects of resistance modifiers such as BzDHPs and promethazine will be studied  •
on an E. coli K12 LE 140/ F’lac as model. The change in the resistance of S. aureus after plasmid 
curing will be following by the changes in antibiotic sensitivity.
Fluoro-luminometric measurements will be reported for the differentiation of bacterial growth and  •
viability in the combined application of AMP and PZ.
3. MATERIALS AND METHODS
3.1. Materials
Antibiotics: Ampicillin (AMP) was purchased from (Beecham Research Laboratories, England), 
erythromycin (ERY) was from (Richter Gedeon Rt., Budapest, Hungary), and oxacillin (Oxa), tetracycline 
(TC) and gentamicin (GENT) were from (Chinoin, Budapest, Hungary).
Resistance modifiers: New resistance modifiers: fifteen substituted dihydropyridines were synthetized 
previously (1). The structures of the BzDHPs are reported below (GB1-GB15). 
Eleven acetyldihydropyridines of NP analogues were synthetsized as previously described (2).
The standards were obtained from the indicated companies: verapamil (VP) (Chinoin, Budapest, 
Hungary), nifedipine (NP) (Aldrich, N7634, St. Louis, MO. U.S.A.), promethazine (PZ) (Pipolphen, EGIS, 
Budapest, Hungary), methylene blue (MB) (Reanal, Budapest, Hungary), clomipramine (CP) (Anaphranil, 
Ciba, Geigy, Basel, Switzerland), and imipramine (Melipramine, EGIS, Budapest, Hungary).
Painting: MTT: 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide) /thiazolyl blue/  (Sigma, St. 
Louis MO, USA).
Bacterials strains: Escherichia coli K12 LE 140/F’lac tsx, str, Δ lac, su, λ–òr, mal, (F− prime lac+) 
laboratory strain and two clinical isolates, E. coli AMPsens • ERYres and E. coli AMPres • ERYres were  kindly 
provided by the Public Health Institute of Csongrad County.
 E. coli MC1061/ cl+ ∆ (ara leu) 7697 ∆lac X74 galU galK hsr hsm  +rpsl  araD 139 
Clinical isolates: P. aeruginosa (1), S. epidermidis (1), S. aureus metres (MRSA) (4) and 
                           S. aureus metsens (MSSA) (4).
Standard strains: E. coli (ATCC 25 922), S. aureus Rosenbach (ATCC 25 923) and 
                            P. aeruginosa (ATCC 27 853).
Culture media: The antibacterial effects of the tested compounds were studied by using minimal 
tryptone yeast extract (MTY) nutrient broth, containing 1.0 g NH4Cl, 7.0 g K2HPO4,
3.0 g NaH2PO4, 0.8 g NaCl, 1.0 g D-glucose, 10.0 g Bacto tryptone (Difco) and 1.0 g yeast extract 
(Difco) in 1.0 L distilled water at pH 7.2. The MTY plates contained 1.5% agar-agar.
EMB (eosin-methylene blue) agar plates were used for the differentiation of lac-negative (lac-) pink and 
lac-positíve (lac+) deep-purple colonies.
LB-broth: Luria-Bertani broth (3).
3.2. Methods
• Determination of minimum inhibitory concentration (MIC): Overnight cultures of
bacterial strains were diluted (to 10-4  in 2 x MTY broth) on aliquots of 50 µL, transferred to a 
96-well microplate, and 50 µL of different concentrations of antibiotic or resistance modifier solution was 




• Checkerboard method: The checkerboard method is the technique used most frequently to assess 
antibacterial combinations in vitro. The results of the combined use of antibiotics and resistance modifiers 
were evaluated according to the literature, as synergism, additivity, indifferent or antagonism (5). 
• Time-killing method: The colony counts of viable cell numbers were determined in various intervals 
in the presence of antibiotics or resistance modifiers. The antimicrobial effect was  tested by a literature 
method (5).
• Elimination of F’lac plasmid: From an overnight preculture of E. coli  K12 LE 140/F’lac, a 1:104 
dilution was prepared and 0.05 mL (approximately 5 x 103 cells) aliquots were inoculated into 5.0 mL MTY 
broth containing the compounds. Cultures were incubated at 37 °C for 24 h without shaking. Different 
dilutions were made from the tube cultures showing bacterial growth, the cultures were diluted in isotonic 
saline and 0.1 mL of each dilution was spread on EMB agar. The plates were incubated at 37 °C for 24 h 
(6).  
• Elimination of R-plasmid: Growing cultures were supplemented with different concent-rations of 
curing agents. From tubes showing growth, different dilutions were prepared and 0.1 mL samples were 
plated on MTY plates in cases of R-plasmid carrying strains. The velvet replica from master plates was 
made on plates containing antibiotics (7).
• Fluoro-luminometric viability analysis of Escherichia coli cells using an GFP-  
   luciferase combination: 
    Plasmid: pEGFPlucTet / This plasmid was a pUC19-based high-copy number plasmid which contains 
enhanced green fluorescent protein (egfp) gene and luciferase gene (lucFF) of firefly P. pyralis. Genes were 
inserted into the frame with the lacZ initiation codon from pUC19, so that EGFP and luciferase proteins 
expressed from the lac promoter gene-coded tetracycline resistance (Tet) provided plasmid stability during 
the experiments (8).
• Cultivation of bacteria for fluoro-luminometry : Overnight cultures of bacteria were diluted (1:100) 
with fresh LB -broth. Equal volumes of bacterial culture and AMP, PZ or a combination of AMP and PZ 
(or 150 mM NaCl as a control) were mixed in wells of a 96-well plate for fluoro-luminometric analysis and 
optical density measurement to assess the AMP and PZ-dependent killing of the bacteria.
• Fluoro-luminometric analysis : Bacterial cultures (E. coli containing pEGFPlucTet) (100 µl) 
were mixed with 100 µL of various AMP and PZ dilutions. The fluorescence of the cells was measured 
for 0.1 s/well, using 485 nm excitation and 510 nm emission filter sets. Following the fluorescence 
measurements on particular wells at the indicated time points, 100 µL of luciferin solution (0.5 mM 
D-luciferin in 100 mM sodium citrate, pH 5.0) was automatically dispensed into the wells, and the 
bioluminescence of the cells was measured for 1 s/well (9).
4. RESULTS
4.1. Determination of minimum inhibitory concentrations (MICs) of some antibiotics in the presence 
of resistance modifiers 
As concerns the combinations of antibiotics with resistance modifiers against Gram-negative and 
Gram-positive strains when MICs were measured, PZ, MB and CP alone had only limited inhibitory 
activity against E. coli K12 LE 140 F’ lac strain. The combinations of PZ, MB and CP with AMP were 
synergistic against E. coli K12 LE 140 F’ lac strain.
Synergism was not observed with combinations of AMP and VP. Of the four resistance modifiers 
employed, synergism was observed for PZ in combination with TC and ERY, and with the combination of 
MB and ERY on the E. coli K12 LE 140/F’lac strain.
The effect of the combination of GENT and MB against P. aeruginosa was synergistic.
PZ acted synergistically with TC and ERY. The combinations of CP with ERY and TC, MB with ERY 
were synergistic on S. epidermidis. 
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4.2. Antibacterial effects and interactions of antibiotics with 3,5-diacetyl-1,4-dihydro- pyridines 
(AcDHPs) (G1-G11) on E. coli strains
These features were evaluated with checkerboard and time-killing methods.
• Effects of the combination of AcDHPs (G1-G11) with ampicillin
Synergistic effects of seven AcDHPs (G1, G3, G4, G7, G8, G10 and G11) in combination with AMP 
were seen after 24 h on the E. coli K12 LE 140 /F’lac strain. Additive effects were observed for the 
combinations of G2, G5 and G6 with AMP. VP exhibited only an antagonistic effect with AMP on the E. 
coli K12 LE 140 F’lac strain. 
AMP is in combination with G1 was antagonistic against the E. coli AMPsens·ERYres strain. 
As concerns the E. coli AMPres · ERYres clinical isolate, the antibacterial effects of AMP in combination 
with G1-G11 were additive. VP exerted only an indifferent effect with AMP.
• The combinations of AcDHPs (G1-G11) with erythromycin
The AcDHPs (G7-G8) displayed synergistic effects with ERY against E. coli K12 LE 140/F’ lac strain. 
The effects of G2, G3, G10, G11, VP and NP were additive. The actions of the other compounds (G1, G4, 
G5, G6 and G9) in combination with ERY were indifferent.  G7 and G8 compounds in combination with 
ERY were synergistic.   
The combinations of ERY with eleven AcDHPs (G1-G11) exerted additive effects on E. coli 
AMPsens·ERYres.  VP in combination with ERY was indifferent. 
Similarly, the combinations of the AcDHPs (G1-G11) with ERY exhibited additive effects on E. coli 
AMPres·ERYres strain. VP and NP in combination with ERY were additive effects. 
4.3. Antibacterial effects and interactions of 3,5-dibenzoyl-1,4-dihydropyridines (BzDHPs) (GB1-
GB15) 
Three different E. coli strains was teseted: E. coli K12 LE 140/F’lac, E. coli AMPsens• ERYres and E. 
coli AMPres ·ERYres.
On the E. coli K12 LE 140/F’lac strain, fifteen compounds (GB1-GB15) were studied in combination 
with ERY. Only GB12 with ERY gave a synergistic effect. Compounds GB2, GB5, GB8, GB9, GB11, 
GB13 in combination with ERY were not active.
On the E. coli AMPsens·ERYres strain, GB2, GB3 and GB5 with ERY displayed synergistic effects. 
GB7, GB9, GB11 and GB14 showed additive activity. GB8, GB10, GB13 and GB15 in combination with 
ERY were indifferent.
On the E. coli AMPres·ERYres, the combination of GB2, GB5, GB6 with ERY had a synergistic effect. 
Compounds, GB8 - GB15 in the combination were indifferent. GB1, GB3, GB4 and GB7 showed additive 
activity.
4 4. Antibacterial effects and interactions of antibiotics and resistance modifiers on methicillin-
resistant Staphylococcus aureus strains
In our current research we studied the interactions of four different class representative antibiotics 
(AMP, ERY, GENT, Oxa and TC) and different resistance modifiers (PZ, imipramine, omeprazol, 
yohimbine and VP) on four methicillin-resistant and four methicillin- sensitive S. aureus strains with a 
checkerboard method.
The combination of Oxa with PZ exhibited synergy on only one of the four methicillin-resistant S. 
aureus strains. For the four methicillin-sensitive strains, only additive effects were found. The other 
resistance modifiers, imipramine and VP, in combination with Oxa were ineffective. 
In the control experiment, the combination of Oxa and VP resulted in additive effect on the methicillin- 
sensitive S. aureus strains.
4.5. Studies on plasmid elimination
The metabolic plasmid elimination was studied with a broth dilution method on the E. coli K12 LE 
140 F’ lac strain. Since GB12 displayed the most effective antibacterial activity in combination with ERY, 
it was decided to study whether this combination with PZ induced plasmid elimination on E. coli K12 LE 
140/F’lac cells. This combination of GB12: 16 µg/mL and PZ resulted in a noteworthy increase in plasmid 
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elimination. The F' lac plasmid elimination of PZ alone was 28.5%, whereas that of PZ with GB12 was 
62 %.
The R-plasmid elimination effect of PZ at 100 µg/mL was studied by a broth dilution method on the S. 
aureus 13137 strain plasmid-mediated methicillin resistance. The R-plasmid elimination was determined 
with a replica method. The antibiotic-sensitive colonies were isolated: 3.9 % for ERY, 4.4 % for TC and 
3.7 % for Oxa.
4.6. Fluoro-luminometric analysis of drug interaction between ampicillin and promethazine on 
Escherichia coli containing green fluorescence protein and luciferase
In the presence of both AMP and PZ, the growth of E. coli was substantially suppressed. The results 
obtained by fluorescence and bioluminescence revealed that the combination of AMP and PZ functions 
synergistically as concerns the antibacterial effect. It is obvious that PZ in low concentrations significantly 
enhanced the activity of AMP against the tested E. coli strain. Thus, clear synergism was observed between 
AMP and PZ.
DISCUSSION
The direct antibacterial activity of Ca2+-channel antagonists and phenothiazines against antibiotic-
resistant bacteria has been studied for many years.  The use of these compounds for the management of 
bacterial infections has not been attempted because the concentrations that inhibit bacterial growth in vitro 
are not achievable clinically. Some of these compounds are also known to produce serious side-effects. The 
administration of clinical doses of VP or PZ has been questioned.
Nevertheless, PZ as an adjuvant to conventional antibiotic therapy for serious paediatric bacterial 
infections such as chronic pyelonephritis caused by polyresistant bacteria has yielded significant success 
as compared with the use of the antibiotic alone. This enhancement of antibiotic activity against selected 
species of bacteria has been reported in vivo with various phenothiazines in combination with GENT and 
other drugs in vitro .
The mechanism by which phenothiazine derivatives and structurally similar compounds enhance the 
activity of conventional antibiotics has been postulated to involve plasmid curing and functional alterations 
in the plasma membrane of the bacteria, to the extent that the transport mechanisms are affected. The direct 
action of the phenothiazines and other resistance modifiers on the permeability of the membrane itself has 
also been considered. 
The  • E. coli, P. aeruginosa and S. epidermidis proved moderately sensitive to the direct antibacterial 
action of various resistance modifiers. In combinations, the various resistance modifiers were able to 
increase the activities of all the different antibiotics (10). Synergistic interactions were found between 
AMP plus PZ, or MB or CP. Similarly synergy was demonstrated between TC and PZ, ERY and PZ, 
or ERY and MB on an E. coli laboratory strain in vitro. 
Synergic interactions between various peptides and ERY were observed when tested against E. coli. A 
number of synergy studies have been performed on antimicrobial peptides. Similar synergistic effects 
were found for TC plus PZ, or TC plus CP, or ERY plus PZ, and ERY plus CP on S. epidermidis 
strains in vitro. Synergism was observed for the combination of GENT plus MB on the P. aeruginosa 
strain in vitro.
The activities of these antibiotics and resistance modifiers at the level of the plasma membrane 
are modified by the chemical structures of the compounds and by the nature of the cell wall. The 
activity, when present, is a result of the interaction of the antibiotic and the compound external to the 
membrane itself. 
Synergistic or additive effects of newly synthetized AcDHPs (G1–G11) with AMP or ERY have  •
been shown on the E. coli laboratory strain and the E. coli AMPsens·ERYres strain. These effects of 
synergistic or additive combinations are supported by additional experiments. The present results 
clearly define the effects of combinations of AcDHP analogues (G1–G11) with AMP or ERY, which 
are of some interest as substituted dihydropyridines in structure-activity relationships. Apparently the 
synergism between Ca2+ -channel blockers and antibiotics depends on the chemical structures of the 
dihydropyridines tested (11).  
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The results suggest that other groups of substituted dihydropyridines e.g. the BzDHPs, may contain 
resistance modifiers, similarly to VP or NP, the compounds may act as a Ca2+ -channel blockers, and 
hence they may inhibit the efflux of ERY or other macrolides. The enhancing effect of the BzHDPs 
on the antibacterial action of some macrolides may serve as an important model for drug design in 
the treatment of infections, as previously found for resistance modifiers based on antiplasmid effects 
(12).
The interaction of different antibiotics (AMP, ERY, GENT, Oxa and TC) with resistance modifiers  •
(PZ, imipramine, omeprasol, yohimbine, VP) were studie on 4 methicillin-resistant an 4 methicillin-
sensitive S. aureus strains with checkerboard method. The 8 S. aureus strains were sensitive to GENT. 
The Oxa and PZ combination showed a synergistic effect on a methicillin-resistant S. aureus 13137 
strain, it was additive in 4 instances, indifferent to 2 strains. 
The antiplasmid effects of some of the newly synthetized BzDHP compounds have been revealed.  •
GB12 and PZ in combination enhanced F’ lac plasmid elimination, which means that there is possible 
synergism between resistance modifiers.
The evidence for beneficial interactions between resistance modifier and antibiotics was defined  •
through the viability and killing of E. coli, measured on a real-time basis by using a fluoro-
luminometric device. Bacteria were made fluorescent and bioluminescent by the expression of 
gfp and insect luciferase (lucFF) genes. The green fluorescent protein, which accumulates in cells 
during growth, and therefore governs the measured fluorescence signal, is proportional to the total 
number of cells. The luciferase reaction is dependent on the ATP produced by living cells, so that the 
bioluminescence level is a direct measure of the viable cells. Luminescence studies confirmed the 
strong synergistic bactericidal interactions between antibiotics and non-antibiotics in the GFP bacteria 
labelled luc gene. Fluoro-luminometric single cell analysis is a reliable method for determination of 
the total cell number and the number of living cells.
SUMMARY
This thesis present a brief overview on a new perspective in drug design against drug resistance 
phenomena, focusing on the plasmid-mediated infectious antibiotic resistance of bacteria. The resistance 
modifiers and their chemical structures were analysed in detail as concerns synergistic action with some 
antibiotics. Correlations were analysed between the synergistic effects and the chemical structures of 
various potential resistance reversal drugs.
The individual activities of antibiotics such as AMP, TC, ERY and GENT in combination with  •
compounds known to modify bacterial resistance to the given antibiotics were studied by using 
the checkerboard and time-killing methods. The combination of PZ with AMP, TC or ERY or 
the combination of MB and ERY produced significant synergistic activity against E. coli. The 
combinations of CP with either TC or ERY were synergistic. PZ and ERY or VP and AMP proved to 
be synergistic combinations against S. epidermidis. Synergy against P. aeruginosa was displayed by 
the combination of MB and GENT.
Fifteen BzDHPs, (GB1-GB15) as NP analogues and NP as control were tested with different antibiotic  •
sensitivities on E. coli strains. The compounds alone had relatively high MIC values on these strains. 
In combination with ERY, GB1, GB3, GB4, GB6, GB7, GB10 and GB12 reduced the MIC of ERY.
When the BzDHPs were tested on the E. coli ERY
res • 
AMPsens strain isolated from a clinical specimen, 
the reductions in the MIC were similar to those observed on other E. coli strains. With a polyresistant 
clinical isolate E. coli strain, the MIC of ERY was slightly reduced in the presence of GB1-GB7. 
Compound GB12 was the most effective in enhancing the activity of ERY, and was selected for 
plasmid elimination studies. 
Eleven analogues of NP (3,5-diacetyl-1,4-dihydropyridines)/G1-G11/ exhibited synergistic interactions  •
with AMP and ERY on an E. coli laboratory strain. The antibacterial effect of AMP was enhanced 
by most of these analogues. The actions of 2 of the 11 compounds (G7 and G8) with ERY were 
synergistic and four were additive. With an  clinical isolate of E. coli AMP 
sens • 
ERY res, compound 
G1 antagonized the antibacterial effect of AMP. Synergistic effects was found for the combinations 
of ERY with G4, G5, G6 or G7.
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The antiplasmid effects os some the newly synthetized BzDHP compounds have been revealed.  •
GB12 and PZ in combination enhanced F’ lac plasmid elimination, which means that ther a possible 
synergism between resistance modifiers.
The fluorescence-luminescence-based method proved very useful for various bacterial viability and  •
killing measurements. In the presence of both AMP and PZ, the growth of E. coli was substantially 
suppressed. The results obtained by fluorescence-bioluminescence suggest that the combinations of 
AMP and PZ function synergistically. It is obvious that PZ enhances the activity of AMP against E. 
coli significantly. 
7. REFERENCES
Kawase M, Shah A, Gaveriya H, Motohashi N, Sakagami H, Varga J and  Molnár J: 1. 
3,5-dibenzoyl-1,4-dihydropyridines: Synthesis and MDR reversal in tumor cells. Biorg. 
Med. Chem.  10: 1051-1055, 2002. 
Shah A, Gaveriya H, Motohashi N, Kawase M, Saito S, Sakagami H, Satoh K, Tada 2. 
Y, Solymosi A, Wolfrad K and MolnárJ: 3,5-diacetyl-1,4-dihydropyridines: Synthesis 
and MDR  reversal in tumor cells. Anticancer Res. 20: 373-377, 2000.
Lektinen J, Virta M and Lilius EM: 3. Fluoro-luminometric real-time measurement of 
bacterial viability and killing. J. Microbiol. Methods. 55: 173-186, 2003. 
National Committee for Clinical Laboratory Standards (NCCLS):  4. Methods for 
dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. 
Approved  standard M7-A2. National Committee for Clinical Laboratory Standars, 
Villanova, Pa. 1990.
 5. Eliopoulos GM and Moellering RC: Antimicrobial combinations. In: Lorian V. editor.
Antibiotics in Laboratory in Medicine, 3rd. ed., The Williams & Wilkins Co., Baltimore, 
MD. USA. pp. 434-441, 1991.
Mándi Y, Molnár J, Holland LB and Béládi I:6.  Efficient curing of an Escherichia coli 
F-prime plasmid by phenothiazines. Genet Res. 26: 109-111, 1975.
Lederberg J and Lederberg EM: 7. Replica plating and indirect selection of bacterial 
mutants. J. Bacteriol. 63: 339-406, 1952. 
Vieira J and Messing J: 8. The pUC plasmids, an M13mp7-derived system for insertion 
mutagenesis and sequencing with synthetic universal primers. Gene. 19: 259-268, 1982. 
Veal DA, Deere D, Ferrari B. Piper J and Attfield PV:9.  Fluorescence staining and flow 
cytometry for monitoring microbial cells. J. Immunol. Methods. 243: 191-210, 2000. 
Gunics Gy, Motohashi N, Farkas S and Molnár J:10.  Interaction between antibiotics and 
non-conventional antibiotics on different bacteria. Int. J. Antimicrob. Agents. 14: 
 239-242, 2000.
Gunics Gy, Farkas S, Motohashi N, Shah A, Harsukh G, Kawase M and Molnár J: 11. 
Interaction between 3,5-diacetyl-1,4-dihydropyridines and ampicillin and erythromycin 
on different E. coli strains. Int. J. Antimicrob. Agents. 20: 227-229, 2002.
Gunics Gy, Motohashi N, Molnár J, Farkas S, Kawase M, Saito S and Shah A: 12. 
Enhanced antibacterial effect of erythromycin in the presence of 3,5-dibenzoyl- 
1,4-dihydropyridines. Anticanser Res. 21: 269-273, 2001.
PUBLICATION RELATED TO THE THESIS
Publications
Tariné Gombkötő Zs, 1. Gunics Gy,  ifj. Regdon G and Selmeczi B : Antibakteriális 
hatású vaginális kúpok formálása és in vitro vizsgálata. In vitro membrándiffúziós és 
mikrobiológiai vizsgálatok. Acta Pharmaceutica Hung. 62: 302-311, 1992. IF: 0,51
Gunics Gy, Motohashi N, Amaral L, Farkas S and Molnár J:2.  Interaction between 
antibiotics and non-conventional antibiotics on bacteria. Int. J. Antimicrob. Agents. 14: 
239-242, 2000. IF: 1,584
ACTA SANA
14
Gunics Gy, Motohashi N, Molnár J, Farkas S, Kawase M, Saito S and Shah A: Enhanced 3. 
antibacterial effect of erythromycin in the presence of 3,5-dibenzoyl- 1,4-dihydropyridines. 
Anticanser Res. 21: 269-273, 2001. IF: 1,447
Gunics Gy, Farkas S, Motohashi N, Shah A, Harsukh G, Kawase M and Molnár J: 4. 
Interaction between 3,5-diacetyl-1,4-dihidropyridines and ampicillin and erythromycin 
on different E. coli strains. Int. J. Antimicrob. Agents. 20: 227-229, 2002. IF: 1,584
Proceedings
Farkas S, 5. Gunics Gy, Hegedüs A and Kecskés M: Growth of Rhizobium and Escherichia 
strains by some metal ions. Environment Protection Modern Studies in Ecology and 
Microbiology. Uzhgorod, 2: 163-166, 1997.
Farkas S, 6. Gunics Gy, Hegedüs A and Kecskés M: Susceptibility of the Rhizobium 
and E. coli strains to different antibiotics. 13 th International Congress of the Hungarian 
Society for Microbiology, Budapest, 2: 27-29. 1999.
Gunics Gy, Farkas S, Motohashi N, Shah A, Kawase M, Saito S and Molnár J: 7. The  
modification of antibiotic resistance in some Gram-negatíve bacteria. 13 th International 
Congress of the Hungarian Society for Microbiology, Budapest, 2: 33-35, 1999.
Farkas S, 8. Gunics Gy, Kecskés M Jr., H. A. E. Bayoumi Hamuda and Kecskés M: Effect 
of ampicillin and gentamicin on E. coli, Bradyrhizobium, Rhizobizum and Sinorhizobium 
strains modified by promethazine. Scientific of Szabolcs-Szatmár-Bereg County of Acad. 
Sci. Hung. Nyíregyháza, 2: 353-362, 2002.
Abstracts
Molnár J, Csúri K, 9. Gunics Gy, Hassan H. Khalid, Csiszár K and Nakamura M: 
Instability of plasmids in some bacterie induced by xenobiotics. Acta Microbiol. Acad. 
Sci. Hung. 38: 189, 1991.
Gunics Gy, Farkas S and Molnár J: 10. Elimination of antibiotic resistance of Acinetobacter 
calcoaceticus strains by promethazine, imipramine and SDS. Acta Microbiol. Immun. 
Hung.  44:  405, 1997.
Farkas S, 11. Gunics Gy, Hegedüs A and Kecskés M: Effect of cadmium, selenium and 
silver on Escherichia coli and Rhizobium strains. Acta Microbiol. Immun. Hung. 44: 437, 
1997.
Gunics Gy, Motohashi N, Farkas S and Molnár J:12.  Effect of some resistance 
modifiers on the action of ampicillin and erythromycin. 21 st International Congress 
of Chemotherapy, Birmingham, UK, 4-7 July, J. Antimicrob. Chemother. Suppl. A. 
pp. 87-88,1999. IF: 2,563.
Gunics Gy, Farkas S and Molnár J:13.  Synergistic effect of antiplasmid compounds with 
antibiotics. Acta Microbiol. Immun. Hung. 46: pp.122, 1999.
Farkas S, 14. Gunics Gy, Hegedüs A and Kecskés M : Susceptibility of Rhizobium and  
E. coli strains to different antibiotics. Acta Microbiol. Immun. Hung. 47: pp. 308, 2000.
Gunics Gy, Farkas S, Motohashi N, Shah A, Kawase M, Saito S, Amaral L and 15. 
Molnár J: Dihydropyridines as resistance modifiers in vitro on E. coli strains. Third 
Europen Congress of Chemotherapy, Madrid, Spain, 8-9 May. J. Antimicrob. Chemother. 
Suppl. A. pp. 85, 2000. IF: 2,563. 
Presentations 
Gunics Gy and Molnár J: 16. Sztereoizomérek plazmidtörlő hatása. Dr. Cserháti István 
emlékülés, Szeged, 1988, jún, 21-23.
Gunics Gy, Molnár J:17.  A kinin és kinidin hatása az Escherichia coli plasmid hordozására. 
Magyar Kemoterápiai Társaság Konferenciája, Hajdúszoboszló, 1988, máj. 01-04.
Farkas S, Péntek M, 18. Gunics Gy and Molnár J: Antiplasmid effect of sililsubstituted 




Farkas S, 19. Gunics Gy and Molnár J: Investigation of the penicilline-resistance and beta-
hemolysis loss on Staphylococcus aureus strains. Congress of the Hungarian Society for 
Chemotherapy, Hajdúszoboszló, 10-13, May. 1989.
Farkas S, 20. Gunics Gy and Molnár J: Alteration of attribution of  Staphylococcus  
aureus strains by plasmid elimination compounds. Congress of the Hungarian Society for 
Microbiology, Eger, 24-26, Aug. 1989.
Gunics Gy, Fekete J, Tóth G, Földes J and Molnár J: 21. R-plazmidok eliminálása 
Acinetobacter anitratus törzsekből. MMT Nagygyűlése, Eger, aug. 24-26. 1989. 
Tariné Gombkötő Zs, Regdon G, 22. Gunics Gy, Molnár J and Selmeczi B: Kloram-
fenikol, szulfonamidin, gentamicin-szulfát tartalmú kúpok készítése és mikrobiológiai 
vizsgálata. XII. Országos Gyógyszertechnológiai Konferencia és 2. Gyógyszerészeti és  
Biogyógyszerészeti Bilaterális Szimpózium. Hévíz, okt. 8-10, 1990.
Molnár J, Csúri K, 23. Gunics Gy, Hassan H. Khalid, Csiszár K and Nakamura N: 
Instability of plasmids in some bacteria induced by xenobiotics. 11th Hungarian Congress 
of Microbiology, 1991, Aug. 22-24, Budapest.
Tariné Gombkötő Zs, ifj. Regdon G, Molnár J, 24. Gunics Gy and Selmeczi B:  Antibakteriális 
hatású vaginális kúpok formálása és in vitro vizsgálata. Csongrád Megyei Orvos-
Gyógyszerész Napok, Makó, 1992, okt. 9-10. 
Farkas S, 25. Gunics Gy, Hegedüs A and Kecskés M: Antibacterial effect plasmid 
elimination and inhibition of R144 plasmid transfer by triflupromazine and trimipramine 
in Escherichia coli and Rhizobium strains. Szabolcs-Szatmár-Bereg County Academic 
Committee IX. International Congress of Microbiology, Nyíregyháza, 4-5, Oct. 1996.
Farkas S, Hegedüs A, 26. Gunics Gy and Kecskés M: Growth of Rhizobium and 
Escherichia strains stressed by some metal ions. Environment Protection Congress, 
Uzhgorod, 13-16. May, 1997.
Farkas S, Hegedüs A, 27. Gunics Gy and Kecskés M: Effect of cadmium, selenium and 
silver ions to Escherichia coli and Rhizobium strains. Congress of the Hungarian Society 
for Microbiology, Szekszárd, 25-27, Aug. 1997.
Gunics Gy, Farkas S and Molnár J: 28. Elimination of antibiotic resistance from Acineto-
bacter calcoaceticus strains in the presence promethazine, imipramine and SDS. Congress 
of the Hungarian Society for Microbiology, Szekszárd, 25-27, Aug. 1997.
Gunics Gy, Farkas S and Molnár J: 29. Interaction investigation of phenothiazines and 
related compounds with antibiotics. 13 th Conference of the Hungarian Society for 
Chemoteherapy, Debrecen, 2-5, Jun. 1998.
Gunics Gy, Farkas S and Molnár J: 30. Synergistic effect of antiplasmid compounds with 
different antibiotics. Congress of the Hungarian Society for Microbiology, Miskolc, 
24-26, Aug. 1998.
Gunics Gy, Motohashi N, Farkas S and Molnár J: 31. Effect of some resistance modifiers  
on the action Ampicillin and Erythromycin. 21 st International Congress of Chemotherapy, 
Birmingham, UK, 4-7 July, 1999.
Gunics Gy, Farkas S, Motohashi N, Shah A, Kawase S, Saito S and Molnár J: 32. The 
modification of antibiotic resistance on some gram-negative bacteria. 13 th International 
Congress of the Hungarian Society for Microbiology, Budapest, Aug 30- Sept 1, 1999.
Molnár J, 33. Gunics Gy and Miskolci Cs: Models for reversal of resistance in bacteria and 
fungi. 13 th International Congress of the Hungarian Society for Microbiology, Budapest, 
Aug 30-Sept 1, 1999.
Farkas S, 34. Gunics Gy, Hegedüs A and Kecskés M: Susceptibility of the Rhizobium 
and E. coli strains to different antibiotics. 13 th International Congress of the Hungarian 
Society for Microbiology, Budapest, Aug 30-Sept 1, 1999. 
Gunics Gy, Farkas S, Motohashi N, Shah A, Kawase M,  Saito S, Amaral L and 35. 
Molnár J: Dihydropyridines as resistance modifiers in vitro E. coli strains. Third Europen 
Congress of Chemotherapy, Madrid, Spain, 8-9, May, 2000. 
ACTA SANA
16
Gunics Gy, Motohashi N, Amaral L and Molnár J: 36. Antibiotikum rezisztencia 
módosítása néhány Gram-negativ baktériumoknál in vitro. Magyar Kemoterápiai 
Társaság XV. Konferencia. Hajdúszoboszló, 2002, jún. 07-09.
Gunics Gy, Motohashi N and Molnár J:37.  Az erythromycin antibakteriális hatásának 
módosítása dihydropyridinek jelenlétében. “First Joint meeting of the Slovenian Society for 
Microbiology and the Hungarian Society for Microbiology”, 2000. Keszthely, aug. 24-26.
Molnár J, 38. Gunics Gy, Miskolci Cs and Wolfrád K: Az antibiotikum rezisztencia  
reverziójának modelljei. “First Joint Meeting of the Slovenian Society for Microbiology 
and the Hungarian Society for Microbiology”, 2000. Keszthely, aug. 24-26.
Farkas S, Bayoumi Hamuda Hosam, E. A. F., Kecskés M Jr., 39. Gunics Gy and Kecskés 
M: Effect of Ampicillin and gentamicin on E. coli, Bradyrhizobium, Rhizobium and 
Sinorhizobium strains modified by promethazine. Scientific of Szabolcs-Szatmár-Bereg 
County of Acad. Sci. Hung. Nyíregyháza, 29. Sept, 2002.
Gunics Gy and Molnár J:40.  Antibiotikumok és fenotiazin-származékok antibakteriális hatása 
Gram-negativ baktériumtörzseken. MMT Nagygyűlése, Balatonfüred. 2002, okt. 8-10.
Gunics Gy and Molnár J:41.  Antibiotikumok kölcsönhatásának vizsgálata dihydropyridin-
származékokkal. SZAB Orvostudományok Szakbizottsági Ülése, Szeged, 2003. ápr. 15




Szegedi Tudományegyetem Gyógyszerésztudományi Kar 
Department of Medical Microbiology and Immunobiology
e-mail: ggyongyi@etszk.u-szeged.hu
Bevezetés
Az utóbbi években világszerte az antibiotikum-, illetve kemoterápiás szerekre re-
zisztens mikroorganizmusok elterjedését figyelték meg, különösen a nozokomiális 
fertőzéseket okozó mikróbák körében. Nem ritka, hogy bizonyos baktériumfajok izolá-
tumai 70-90 %-ban rezisztensek egyes (régebben hatásos) antibiotikumokra. Az egyes 
antibioti-kumokra kialakult rezisztencia mellett az egyidejűleg több (szerkezetileg 
eltérő) gyógyszerre kialakult polyrezisztencia nemcsak mikroorganizmusoknál, de a 
daganatsejteknél is előfordul az ún. multidrog-rezisztencia (mdr). 
A rezisztencia (R)-plazmid biztosítja a baktériumok szaporodását az antibiotikum 
jelenlétében. A baktérium ezt a tulajdonságát nemcsak az utódsejtjeinek örökíti át, 
hanem a környezetében lévő más baktériumoknak is átadhatja.
Az antibakteriális szerekkel szembeni rezisztencia típusok közül a legveszélyesebb, az 
ún. fertőző vagy plazmidok által közvetített rezisztencia.
A rezisztencia ellen általában új, a korábbiaktól eltérő szerkezetű és hatású gyógyszerek 
kifejlesztése az egyik kézenfekvő megoldás.
A másik út: bizonyos antibiotikum kombinációk célzott alkalmazása, melynek során a 
baktériumpopulációban egy-egy szerre spontán kialakult baktériumrezisztens mután-
sok a kombinációk egy második tagjával elpusztíthatók. A kombinált kemoterápiát 
csak súlyos fertőzésekben alkalmazzák, mivel többszörösen rezisztens sejtek kiszelek-
tálódásával járhat. 
A harmadik megoldás: az antibiotikum rezisztencia teljes megszüntetése jelenleg pusz-
tán elméleti jelentőségű.
Molnár és mtsai már az 1970-es években megállapították, hogy több különböző gyógy-
szernek is van antiplazmid hatása pl. chlorpromazin, promethazin, stb. 
Az a tény, hogy egymástól távol álló baktériumfajok között is létrejöhet a rezisztencia-
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plazmidok átvitele, különösen indokolttá tette, hogy a már ismert gyógyszerek és az 
újonnan szintetizált vegyületek hatását a baktériumok különböző csoportjain vizs-
gáljuk.
Célkitüzések
A kemoterápia újabb antibiotikumok kutatása mellett több fontos kérdés tanul-
mányozását tartja napirenden, többek között az új gyógyszerkombinációk alkalmazását. 
Kisérleteimben a modellként alkalmazott rezisztens laboratóriumi és klinikai törzsekre 
hatásos gyógyszerkombinációk modelljét tanulmányoztam in vitro. 
1. A baktériumok antibiotikum (ampicillin, chloramphenicol, erythromycin, tetracyc-
lin) érzékenységét, továbbá a rezisztencia módosítók (promethazin, clomipramin, vera-
pamil) minimális gátló koncentrációját (MIC) meghatároztam (E. coli, P. aeruginosa, 
S. aureus  és  S. epidermidis) baktériumtörzseken.
2. Különböző újonnan szintetizált Ca2+-csatornablokkolók, nifedipin analóg vegyü-
letek 3,5-dibenzoyl-1,4-dihydropyridinek (BzDHP) /GB1-GB15/ és 3,5-diacetyl-1,4-
dihydro-pyridinek (AcDHP) /G1-G11/ antibakteriális hatását tanulmányoztam klinikai 
mintákból származó rezisztens  E. coli törzseken. 
3. A különböző antibiotikumok (ampicillin, erythromycin, chloramphenicol, tetracyc-
lin) és rezisztencia módosítók (AcDHP, BzDHP, nifedipin és verapamil) kombinációját 
vizsgáltam Gram-negatív és Gram-pozitív törzseken Checkerboard módszerrel. Az 
oxacillin hatását kombinációban promethazinnal, verapamillal vagy imipraminnal 
tanulmányoztam klinikai Gram-pozitiv törzseken.
4. A rezisztencia módosítók (BzDHP) és a promethazin F’-plazmid elimináló hatását 
vizsgáltam az E. coli K12 LE 140 F’lac törzsön. A promethazin rezisztencia (R)-plazmid 
elimináló hatását  S. aureus 13137 törzsön tanulmányoztam.
5. Az ampicillin és promethazin kombináció antibakteriális hatását E. coli törzsön 
fluoro-luminometriás eljárással vizsgáltam.
Anyag és módszer
Antibiotikumok: ampicillin (AMP), erythromycin (ERY), oxacillin (Oxa), tetracyclin 
(TET) és gentamicin (GENT). 
Rezisztenciamódosítók: verapamil (VP), nifedipin (NP), promethazin (PZ), methylén-
kék (MB), clomipramin (CP) és impramin.
Újonnan szintetizált (2, 3 és 4. C atomon szubsztituált dihydropyridin-származékokat 
vizsgáltam. Nifedipin analóg szerkezetű vegyületek: 3,5-dibenzoyl-1,4-dihydropyri-
dinek (GB1-GB15) és 3,5-diacetyl-1,4-dihydro-pyridinek (G1-G11).
Baktériumtörzsek: Escherichia coli K12 LE 140 F’ lac laboratóriumi törzs,    
                             E. coli AMPsens• ERYres   és  E. coli AMPres• ERYres,  
                             E. coli MC1061 klinikai izolátumok,
                             P. aeruginosa,  S. epidermidis,  (4) S. aureus metres (MRSA),     
                            (4) S. aureus metsens (MSSA) klinikai izolátumok.
Táptalajok: MTY-levestáptalaj, MTY-agar, EMB-agar és LB-levestáptalaj. 
Módszerek
Mikrohigításos módszerrel a minimális gátló koncentráció (MIC) meghatározást 
végeztem. Checkerboard-féle és Time-killing módszer alkalmazásával, az antibioti-
kumok és a rezisztenciamódosítók kölcsönhatását mutattam ki.
Az F’lac plazmid eliminációját: az E. coli K12 LE 140 F’lac baktériumtörzsön tanul-
mányoztam Mándi és mtsai (1975) módszerével.
Az R-plazmid eliminációját: a S. aureus 13137 törzsön tanulmányoztam Lederberg és 
Lederberg (1952) leírása szerint.
GFP-luciferáz kimutatása E. coli sejtekből fluoro-luminometrai eljárással Veal és 
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mtsai (2000) leirása szerint végeztem.
Eredmények
1. Antibiotikumok  és rezisztencia módosítók MIC értéke és kölcsönhatása Gram-
negatív és Gram-pozítiv baktériumtörzseken 
Az E. coli K12 LE 140 F’ lac törzs érzékenységet mutatott ampicillin, tetracyclin, 
erythromycin és gentamicinnel szemben. A promethazin, methylénkék, verapamil 
vagy a clomipraminnal szemben a baktériumtörzs közepes vagy magas szintű rezisz-
tenciáját mutattam ki. A promethazin, methylénkék és clomipramin az ampicillinnel 
kombinációban szinergista hatást mutatott az E. coli K12 LE 140 F’ lac törzzsel szem-
ben.
A rezisztencia módosítók közül a promethazin tetracyclinnel vagy erythromycinnel 
szinergista hatást mutatott. Szinergizmus figyelhető meg a methylénkék és az erythro-
mycin kombinációja esetén is E. coli K12 LE 140 F’ lac törzsön. A gentamicin és me-
thylénkék kombinációja szinergista antibakteriális hatású volt a P. aeruginosa törzzsel 
szemben. A promethazin tetracyclinnel vagy erythromycinnel, valamint a clomipramin 
erythromycinnel vagy tetracyclinnel komkbinációban szinergista hatást mutatott a S. 
epidermidis törzsön.
2. Antibiotikumok és 3,5-diacetyl-1,4-dihydropyridinek (AcDHP) (G1-G11) anti-
bakeriális és és kölcsönhatása  E. coli törzseken
Hét AcDHP / 3,5-dibenzoyl-1,4-dihydropyridinek/  G1, G3, G4, G7, G8, G10 és G11 
az ampicillinnel kombinációban az E. coli K12 LE 140 F’lac törzsön szinergista hatású 
volt.
 A G2, G5, és G6 vegyület az ampicillinnel kombinációban additív hatást mutattak. A 
G1 és az ampicillin kombinációja antagonista hatást mutatott az E. coli AMPsens• ERYres 
törzsön. Az ampicillin és G1-G11 vegyületek kombinációi additív hatást mutattak az E. 
coli AMPres• ERYres klinikai izolátumon. 
Az AcDHP-nek közül G7-G8 vegyületnek szinergista hatása volt az erythromycinnel,  
a G2, G3, G10, G11, verapamil és nifedipin additív hatású volt  az  E. coli K12 LE 140 
F’ lac törzsön. Az erythromycin tizenegy AcDHP vegyülettel G1-G11 kombinációban 
additív hatást mutatott az E. coli AMPsens•ERYres törzsön. Hasonlóképpen az AcDHP 
(G1-G11) kombinációja az erythromycinnel additív hatást mutatott az E. coli 
AMPres•ERYres  törzsön. 
3. Antibiotikumok és 3,5-dibenzoyl-1,4-dihydropyridinek (BzDHP) (GB1-GB15) 
antibakteriális és kölcsönhatása E. coli törzseken
A vegyületek antibakteriális és kölcsönhatását három E. coli törzsön vizsgáltam: E. coli 
K12  LE 140 F’lac, E. coli AMPsens• ERYres és E. coli AMPres • ERYres. 
Tizenöt vegyületet (GB1-GB15) erythromycinnel kombinációban vizsgáltam az E. coli 
K12 LE 140 F’lac törzsön. A GB12 az erythromycinnel kombinációban szinergista 
hatást mutatott.
A GB2, GB3 és GB5 vegyületeknek erythromycinnel szinergista hatásúk volt, valamint 
a GB1, GB4, GB6, GB7, GB9, GB11, GB12 és GB14 additív hatást mutatattak az E. 
coli AMPsens• ERYres törzsön. A GB8, GB10, GB13, és GB15  vegyületeknek erythro-
mycinnel kombinációban indifferens hatásúk volt.
A GB2, GB5, GB6 erythromycinnel kombinációban szinergista hatást mutattak az            
E. coli AMPres•ERYres törzsön.  
4. Antibiotikumok és rezisztencia módosítók antibakteriális és kölcsönhatása a 
methicillin-rezisztens (MRSA) és methicillin-érzékeny (MSSA) Staphylococcus 
aureus törzseken
Különböző antibiotikumok (ampicillin, erythromycin, gentamicin, oxacillin és tetra-
cyclin) és rezisztencia módosítók (promethazin, imipramin, omeprazol, yohimbin és 
verapamil) antibakteriális és kölcsönhatását tanulmányoztam négy methicillin-rezisz-
tens (MRSA) és négy methicillin-érzékeny S. aureus (MSSA) törzsön Checkerboard 
módszerrel. Az oxacillin és promethazin kombinációja a négy methicillin-rezisztens S. 
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aureus (MRSA) törzs közül csak egy törzsre volt szinergista antibakteriális hatással. A 
négy érzékeny törzs (MSSA) esetében a gyógyszerkombináció additív hatású volt. A 
kontroll kísérletben az oxacillin és a verapamil kombináció a methicillin-érzékeny S. 
aureus (MSSA) törzsekre additív hatású volt.
5. A promethazin és 3,5-dibenzoyl-1,4-dihydropyridin-származék GB12 hatása a  
plazmideliminációra
A metabolikus plazmid eliminációt leves hígításos módszerrel vizsgáltam. A promet-
hazin F’ lac plazmidelimináló hatását az E. coli K12 LE 140 törzsön tanulmányoztam. 
A promethazin önmagában 40%-ban, a GB12 vegyülettel kombinációban 60%-os F’ 
lac plazmid eliminációt tapasztaltam. A kombináció szinergista hatással volt az F’ lac 
plazmid eliminációra. A promethazin R-plazmid eliminációs hatását methicillin-rezisz-
tens S. aureus 13137 törzsön vizsgáltam. Az R-plazmid eliminációt replika módszer-
rel határoztam meg. A promethazin  R-plazmid elimináló hatása egy nagyságrenddel 
kisebb volt, mint az F’ lac plazmid eliminációnál. Az antibiotikumokra érzékennyé vált 
(3.9 % erythromycinre, 4,4 % tetracyclinre és 3,7 % oxacillinre) telepeket izoláltam S. 
aureus 13137 MRSA törzsből.
6. Ampicilllin és promethazin kölcsönhatása fluoro-luminometriás eljárással az 
Escherichia coli törzsön
Mind az ampicillin mind a promethazin jelenlétében az E. coli növekedése jelentősen 
visszaesett. A fluoreszcenciás és lumineszcenciás vizsgálatok eredményei azt mutatták, 
hogy az ampicillin és promethazin kombinációja szinergista antibakteriális hatású volt. 
Alacsony koncentrációjú promethazin jelentősen növelte az ampicillin hatását az E. 
coli-val szemben. Az ampicillin és a promethazin között szinergista hatást figyeltem 
meg az E. coli törzsön.
Összefoglalás
Kisérleteim célja volt, felhivni a figyelmet a rezisztenciamódosítók tervezésének új 
lehetőségeire. Tanulmányoztam a rezisztenciamódosítók és a különböző hatásmecha-
nizmusú antibiotikumok kölcsönhatását. 
•  Az antibiotikumoknak, mint az ampicillin, tetracyclin, erythromycin és gentamicin 
hatását módosították a dihydropyridin-származékok kombinációban, melyekről tudott 
a rezisztenciamódosító tulajdonságuk. A promethazin kombinációja az ampicil-
linnel, tetra-cylinnel vagy erythromycinnel illetve a methylénkék és az erythromycin 
kombinációja jelentős szinergista hatást mutatott a laboratóriumi E. coli K12 LE 140 
törzsön. A clomipramin kombinációja a tetracyclinnel vagy az erythromycinnel szin-
ergista hatású volt. A promethazin és az erythromycin, vagy verapamil és ampicillin 
kombinációk szinergista hatást mutattak a S. epidermidis törzsön. A methylénkék és a 
gentamicin kombinációban szinergista hatást mutatott  a  P. aeruginosa törzsön. 
• Tizenöt 3,5-dibenzoyl-1,4-dihydropyridin-származékok (BzDHP) /GB1-GB15/,  
nifedipin analóg vegyület és a nifedipin (kontrollként alkalmazott) vegyületeket vizs-
gáltam különféle antibiotikummal kombinálva polyrezisztens klinikai E. coli törzseken. 
A vegyületekkel szemben a baktériumtörzsek rezisztensek voltak. Az erythromycin 
és a GB12 vegyület kombinációja szinergista hatású volt az E. coli K12 LE 140 törz-
sön. Az erythromycin és a GB1, GB3, GB4, GB6, GB7, GB13 és GB15 vegyületek 
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kombinációja additiv hatást mutattak a laborarótiumi E. coli K12 LE 140 törzsön.
Klinikai mintából származó E coli AMPsens • 
 ERYres törzsön az erythromycin a GB2 és 
GB5 vegyületekkel kombinációban szinergista hatásúak voltak.
A polyrezisztens klinikai izolátum E. coli AMPres• ERYres törzsön az erythromycinnek 
a GB2, GB5 és GB6 vegyületekkel szinergista hatásúk volt. 
• Tizenegy nifedipin analóg (3,5-diacetyl-1,4-dihydropyridin-származékok) (G1-G11) 
szinergista hatást mutatott ampicillinnel a G1, G3, G4, G7, G8, G10 és G11 és eryth-
romycinnel a G7 és G8 kombinációban az E. coli K12 LE 140 laboratóriumi törzsön.         
Az ampicillin antibakteriális hatását a legtöbb diacetyl-dihydropyridin vegyület javi-
totta. A 11 vegyületből kettő G7 és G8 szinergista, négy vegyület additív hatást mutatott 
erythromycinnel az E. coli AMPsens• ERYres törzsön.
• A promethazin F' lac plazmidelimináló hatását fokozta a GB12 vegyület az E. coli 
K12 LE 140 törzsön. A promethazin R-plazmidelimináló hatását a S. aureus 13137 
(MRSA) törzsön figyeltem meg. 
• A fluoreszcencia-lumineszcencia módszer hasznosnak bizonyult a gyógyszer-
kölcsönhatás vizsgálatához. A fluoreszcencia és lumineszcencia mérések eredményei 
azt mutatják, hogy az ampicillin és a promethazin kombináció szinergista hatással 
rendelkezett. 
A promethazin jelentősen növelte az ampicillin hatását az E. coli esetében.
In vitro vizsgálataink hozzájárulhatnak ahhoz, hogy in vivo is javítani tudjuk az egyes 
antibiotikumok hatását különböző polyrezisztens baktériumtörzsek által okozott meg-
betegedések esetén, amely eredmények a gyógyszertervezésben hasznosíthatók lehet-
nek.
